JPWO2020023247A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020023247A5
JPWO2020023247A5 JP2021503750A JP2021503750A JPWO2020023247A5 JP WO2020023247 A5 JPWO2020023247 A5 JP WO2020023247A5 JP 2021503750 A JP2021503750 A JP 2021503750A JP 2021503750 A JP2021503750 A JP 2021503750A JP WO2020023247 A5 JPWO2020023247 A5 JP WO2020023247A5
Authority
JP
Japan
Prior art keywords
optionally substituted
group
metal complex
pharmaceutically acceptable
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021503750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532123A (ja
JP2021532123A5 (https=
JP7395194B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042025 external-priority patent/WO2020023247A1/en
Publication of JP2021532123A publication Critical patent/JP2021532123A/ja
Publication of JPWO2020023247A5 publication Critical patent/JPWO2020023247A5/ja
Publication of JP2021532123A5 publication Critical patent/JP2021532123A5/ja
Application granted granted Critical
Publication of JP7395194B2 publication Critical patent/JP7395194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021503750A 2018-07-23 2019-07-16 外因性および内因性アルブミンを放射性標識するためのイメージング剤 Active JP7395194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702081P 2018-07-23 2018-07-23
US62/702,081 2018-07-23
PCT/US2019/042025 WO2020023247A1 (en) 2018-07-23 2019-07-16 Imaging agents for radiolabeling exogenous and endogenous albumin

Publications (4)

Publication Number Publication Date
JP2021532123A JP2021532123A (ja) 2021-11-25
JPWO2020023247A5 true JPWO2020023247A5 (https=) 2022-07-26
JP2021532123A5 JP2021532123A5 (https=) 2022-07-26
JP7395194B2 JP7395194B2 (ja) 2023-12-11

Family

ID=69181921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503750A Active JP7395194B2 (ja) 2018-07-23 2019-07-16 外因性および内因性アルブミンを放射性標識するためのイメージング剤

Country Status (11)

Country Link
US (1) US20210353783A1 (https=)
EP (1) EP3826685A4 (https=)
JP (1) JP7395194B2 (https=)
KR (1) KR20210035213A (https=)
CN (1) CN112823028A (https=)
AU (1) AU2019309242B2 (https=)
BR (1) BR112021001314A2 (https=)
CA (1) CA3107328A1 (https=)
IL (1) IL280308B2 (https=)
MX (1) MX2021000926A (https=)
WO (1) WO2020023247A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3263646A1 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US20050233307A1 (en) * 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
US20040208828A1 (en) * 2003-02-04 2004-10-21 Lutz Lehmann Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
KR100695744B1 (ko) * 2005-05-03 2007-03-19 한국원자력연구소 디티피에이(ｄｔｐａ) 유도체 및 이들을 이용한 금속 착화물, 이들을 포함하는 방사선원 및 조영제
WO2008070384A2 (en) * 2006-11-06 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of preparing macromolecular contrast agents and uses thereof
FR2909881A1 (fr) * 2006-12-14 2008-06-20 Inst Nat Sante Rech Med Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation
EP2630971B8 (en) * 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems

Similar Documents

Publication Publication Date Title
ES2741207T3 (es) Compuestos citotóxicos y antimitóticos, y métodos de uso de los mismos
US11377473B2 (en) Albumin-binding prodrugs of auristatin E derivatives
AU2006270566B2 (en) Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
JP2020508302A5 (https=)
ES2909486T3 (es) Sistemas de administración para liberación controlada de fármaco
JP2021534168A5 (https=)
JP2014513704A5 (https=)
CA2857398A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
CN113453721B (zh) Metap2抑制剂的生物标志物及其应用
JP2021505541A5 (https=)
JP2017530129A (ja) ツブリシン複合体を用いた癌の治療方法
JP2018062523A5 (https=)
JP2021532123A5 (https=)
JPWO2020023247A5 (https=)
JP2021505551A (ja) メイタンシノイド系薬物送達システム
EP3429572A1 (en) Combination therapy for proliferative diseases
JPWO1992004028A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
TWI324929B (en) Antitumor effect potentiator, antitumor preparation, and method for treating cancer
JPWO2020089687A5 (https=)
CA2409664A1 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
CN105142643A (zh) 药物化合物
RU2021104237A (ru) Средства визуализации для меченного радиоактивным изотопом экзогенного и эндогенного альбумина
CA3083983C (en) Albumin-binding prodrugs of auristatin e derivatives
CN103288673B (zh) 一种铂配体及其配合物
JP6801908B1 (ja) ベネトクラクスの水溶性高分子誘導体